VCNX

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Friedberg AlbertDirector, 10 Percent Owner: $58584.6k shares Grant / ExerciseNov 14, 2024 $58584.6k shares $0.0001 --
Zauderer MauriceDirector, 10 Percent Owner, Officer: President And CEO $968k297.9k shares Grant / ExerciseNov 14, 2024 $150.0K46.2k shares $3.25 --
Friedberg AlbertDirector, 10 Percent Owner: $3.4M1.1M shares Grant / ExerciseNov 14, 2024 $100.0K30.8k shares $3.25 --
Friedberg AlbertDirector, 10 Percent Owner: $3.7M653.2k shares Grant / ExerciseSep 18, 2024 $3.7M653.2k shares $5.64 --
Friedberg AlbertDirector, 10 Percent Owner: $0214.3k shares Grant / ExerciseSep 18, 2024 $1.2M214.3k shares $5.64 --
Zauderer MauriceDirector, 10 Percent Owner, Officer: President And CEO $961k170.5k shares Grant / ExerciseSep 18, 2024 $960.8K170.5k shares $5.64 --

News

globenewswire.comVaccinex Reports 2025 Annual Financial Resultsglobenewswire.comApr 29

Trade VCNX

About Vaccinex, Inc.

Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.

CEO: Maurice Zauderer
IPO Date: Aug 9, 2018

Market Data

Open: $1.09
High: $1.13
Low: $1.09
Volume: 536
Avg Volume: 2.7K
52W High: $1.50
52W Low: $0.31

Valuation

Market Cap: $3.0M
Enterprise Value: $1.9M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-16M
Revenue: $601k
Net Income: $-19M
Cash: $1.1M
Debt: $25k

Events

EarningsAug 10

EPS est. -73.038